LUCD Lucid Diagnostics Inc.

NASDAQ
$0.40

Lucid Diagnostics Inc. (LUCD) is expected to report earnings on February 11, 2027, before the market open. The consensus earnings estimate is a loss of $0.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.3% since its last earnings release on November 12, 2026.

Lucid Diagnostics Inc. Reported In-line with Expectations
Thursday, November 12, 2026 · 8:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 8:00 AM ET
Earnings Whisper
-
vs ($0.07) (GAAP)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.43

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Lucid Diagnostics Inc.

Lucid Diagnostics Inc is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer.

Sector

Healthcare

Industry

Medical Instruments/Supply

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.